Skip to main content
. 2012 Feb 16;106(6):1039–1044. doi: 10.1038/bjc.2012.47

Figure 3.

Figure 3

Biomarker expression in the tumour (pmTOR, pS6K1, pS6Ser235/6 and pS6Ser240/4) at baseline (A, B, C and D) and after two cycles of everolimus (E, F, G and H) in a selected patient who achieved PR.